Cargando…
Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome
OBJECTIVES: SLE and/or antiphospholipid syndrome (SLE/APS) are complex and rare systemic autoimmune diseases that predominantly affect women of childbearing age. Women with SLE/APS are at high risk of developing complications during pregnancy. Therefore, clinical practice guidelines recommend that p...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103373/ https://www.ncbi.nlm.nih.gov/pubmed/33952625 http://dx.doi.org/10.1136/lupus-2020-000472 |
_version_ | 1783689299103842304 |
---|---|
author | Wind, Merlijn Hendriks, Maike van Brussel, Bernadette T J Eikenboom, Jeroen Allaart, Cornelia F Lamb, Hildo J Siebelink, Hans-Marc J Ninaber, Maarten K van Geloven, Nan van Lith, Jan M M Huizinga, Tom W J Rabelink, Ton J Sueters, Marieke Teng, Y K Onno |
author_facet | Wind, Merlijn Hendriks, Maike van Brussel, Bernadette T J Eikenboom, Jeroen Allaart, Cornelia F Lamb, Hildo J Siebelink, Hans-Marc J Ninaber, Maarten K van Geloven, Nan van Lith, Jan M M Huizinga, Tom W J Rabelink, Ton J Sueters, Marieke Teng, Y K Onno |
author_sort | Wind, Merlijn |
collection | PubMed |
description | OBJECTIVES: SLE and/or antiphospholipid syndrome (SLE/APS) are complex and rare systemic autoimmune diseases that predominantly affect women of childbearing age. Women with SLE/APS are at high risk of developing complications during pregnancy. Therefore, clinical practice guidelines recommend that patients with SLE/APS should receive multidisciplinary counselling before getting pregnant. We investigated the clinical effectiveness of implementing a multidisciplinary clinical pathway including prepregnancy counselling of patients with SLE/APS. METHODS: A clinical pathway with specific evaluation and prepregnancy counselling for patients with SLE/APS was developed and implemented in a tertiary, academic hospital setting. Patients were prospectively managed within the clinical pathway from 2014 onwards and compared with a retrospective cohort of patients that was not managed in a clinical pathway. Primary outcome was a combined outcome of disease flares for SLE and thromboembolic events for APS. Secondary outcomes were maternal and fetal pregnancy complications. RESULTS: Seventy-eight patients with 112 pregnancies were included in this study. The primary combined outcome was significantly lower in the pathway cohort (adjusted OR (aOR) 0.20 (95% CI 0.06 to 0.75)) which was predominantly determined by a fivefold risk reduction of SLE flares (aOR 0.22 (95% CI 0.04 to 1.09)). Maternal and fetal pregnancy complications were not different between the cohorts (respectively, aOR 0.91 (95% CI 0.38 to 2.17) and aOR 1.26 (95% CI 0.55 to 2.88)). CONCLUSIONS: The outcomes of this study suggest that patients with SLE/APS with a pregnancy wish benefit from a multidisciplinary clinical pathway including prepregnancy counselling. |
format | Online Article Text |
id | pubmed-8103373 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-81033732021-05-24 Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome Wind, Merlijn Hendriks, Maike van Brussel, Bernadette T J Eikenboom, Jeroen Allaart, Cornelia F Lamb, Hildo J Siebelink, Hans-Marc J Ninaber, Maarten K van Geloven, Nan van Lith, Jan M M Huizinga, Tom W J Rabelink, Ton J Sueters, Marieke Teng, Y K Onno Lupus Sci Med Reproductive health and APS OBJECTIVES: SLE and/or antiphospholipid syndrome (SLE/APS) are complex and rare systemic autoimmune diseases that predominantly affect women of childbearing age. Women with SLE/APS are at high risk of developing complications during pregnancy. Therefore, clinical practice guidelines recommend that patients with SLE/APS should receive multidisciplinary counselling before getting pregnant. We investigated the clinical effectiveness of implementing a multidisciplinary clinical pathway including prepregnancy counselling of patients with SLE/APS. METHODS: A clinical pathway with specific evaluation and prepregnancy counselling for patients with SLE/APS was developed and implemented in a tertiary, academic hospital setting. Patients were prospectively managed within the clinical pathway from 2014 onwards and compared with a retrospective cohort of patients that was not managed in a clinical pathway. Primary outcome was a combined outcome of disease flares for SLE and thromboembolic events for APS. Secondary outcomes were maternal and fetal pregnancy complications. RESULTS: Seventy-eight patients with 112 pregnancies were included in this study. The primary combined outcome was significantly lower in the pathway cohort (adjusted OR (aOR) 0.20 (95% CI 0.06 to 0.75)) which was predominantly determined by a fivefold risk reduction of SLE flares (aOR 0.22 (95% CI 0.04 to 1.09)). Maternal and fetal pregnancy complications were not different between the cohorts (respectively, aOR 0.91 (95% CI 0.38 to 2.17) and aOR 1.26 (95% CI 0.55 to 2.88)). CONCLUSIONS: The outcomes of this study suggest that patients with SLE/APS with a pregnancy wish benefit from a multidisciplinary clinical pathway including prepregnancy counselling. BMJ Publishing Group 2021-05-05 /pmc/articles/PMC8103373/ /pubmed/33952625 http://dx.doi.org/10.1136/lupus-2020-000472 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Reproductive health and APS Wind, Merlijn Hendriks, Maike van Brussel, Bernadette T J Eikenboom, Jeroen Allaart, Cornelia F Lamb, Hildo J Siebelink, Hans-Marc J Ninaber, Maarten K van Geloven, Nan van Lith, Jan M M Huizinga, Tom W J Rabelink, Ton J Sueters, Marieke Teng, Y K Onno Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome |
title | Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome |
title_full | Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome |
title_fullStr | Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome |
title_full_unstemmed | Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome |
title_short | Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome |
title_sort | effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome |
topic | Reproductive health and APS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103373/ https://www.ncbi.nlm.nih.gov/pubmed/33952625 http://dx.doi.org/10.1136/lupus-2020-000472 |
work_keys_str_mv | AT windmerlijn effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome AT hendriksmaike effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome AT vanbrusselbernadettetj effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome AT eikenboomjeroen effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome AT allaartcorneliaf effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome AT lambhildoj effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome AT siebelinkhansmarcj effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome AT ninabermaartenk effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome AT vangelovennan effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome AT vanlithjanmm effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome AT huizingatomwj effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome AT rabelinktonj effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome AT suetersmarieke effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome AT tengykonno effectivenessofamultidisciplinaryclinicalpathwayforwomenwithsystemiclupuserythematosusandorantiphospholipidsyndrome |